NSG 6320 AGNP BOARD EXAM_PRESCRIPTION GASTROENTEROLOGY (85 QUESTIONS)
Question:
A 45-year-old woman has been taking oral omeprazole (Prilosec) 40
... [Show More] mg twice daily for the treatment of gastroesophageal reflux. To discontinue the medication the nurse practitioner would:
advise the patient to stop the medication. reduce the dose by 50% every other day. reduce the dose by 50% weekly. Correct reduce dose by 50% every month.
Explanation:
For patients on a moderate to high dose of a PPI (e.g., omeprazole (Prilosec) 40 mg daily or twice daily), reduce the dose by 50% every week until the patient is on the lowest dose of the medication. For patients on twice daily dosing, the initial reduction can be accomplished by decreasing the dosing to once in the morning before breakfast. Once the patient has completed a week at the lowest dose, the medication can be discontinued.
Question:
Patients receiving long-term proton pump inhibitors (PPIs) are at increased risk for fractures and:
lower extremity edema. extraesophageal symptoms. myocardial infarction. Correct muscle spasms.
Explanation:
Analysis of patients taking PPIs for long periods of time showed an increased risk of myocardial infarctions. This is thought to be related to reduced nitric oxide in the blood vessel walls. The FDA suggests that providers consider periodically obtaining magnesium levels in patients while they are on a PPI. Increased risk of myocardial infarction has not been associated with histamine receptor blockers.
Question:
Ondansetron (Zofran) dosage should be adjusted in patients: with renal insufficiency.
who are pregnant.
who are > 65 years old.
with hepatic impairment. Correct Explanation:
Ondansetron (Zofran) is a 5-HT3 receptor antagonist used for the treatment of nausea and vomiting. Dose limitations are recommended for patients with severe hepatic impairment (Child-Pugh class C); use with caution in mild-moderate hepatic impairment; clearance is decreased and half-life increased in hepatic impairment. No dosage adjustment is recommended with renal insufficiency, pregnancy or in advanced age.
Question:
The antiemetic that does NOT have potential to cause QT prolongation is: promethazine (Phenergan). Correct
chlorpromazine (Thorazine). ondansetron (Zofran). prochlorperazine (Compazine).
Explanation:
Antihistamines such as promethazine and diphenhydramine do not cause QT prolongation. Dopamine and serotonin antagonists are both associated with QT prolongation. Chlorpromazine (Thorazine) and prochlorperazine (Compazine) are
dopamine antagonists. Ondansetron (Zofran) is a serotonin antagonist. If a patient has suspected QT interval prolongation or is taking other medications with which the QT interval prolongation could be additive, a 12-lead EKG is recommended before treatment is initiated.
Question:
Promethazine (Phenergan), a 1st generation antihistamine, is contraindicated in the presence of:
motion sickness. sedation.
asthma. Correct
seasonal allergic rhinitis.
Explanation:
Promethazine (Phenergan) is contraindicated in patients with hypersensitivity reaction to promethazine, other phenothiazines, or any component of the formulation; coma; lower respiratory tract symptoms, including asthma; children younger than 2 years of age; intra-arterial or subcutaneous administration.
Question:
Oral metoclopramide is contraindicated in the patient diagnosed with: migraines.
epilepsy. Correct
diabetes.
renal impairment.
Explanation:
Metoclopramide (Reglan) is contraindicated in situations when gastrointestinal (GI) motility may be dangerous, including mechanical GI obstruction, perforation, or hemorrhage; pheochromocytoma; history of seizure disorder (e.g., epilepsy); and concomitant use with other agents likely to increase extrapyramidal reactions. Caution is advised in patients with renal impairment; dosage adjustment may be needed.
Question:
Hyperosmotic agents and saline laxatives should be avoided or used with caution in patients who have:
chronic constipation. liver disease.
heart failure. Correct
hypothyroidism.
Explanation:
Hyperosmotic agents and saline laxatives may seriously alter fluid and electrolyte balance. This increases the risk for dehydration and electrolyte disturbances, especially hypokalemia. Therefore, the risks versus the benefits should be considered prior to use in patients with heart failure.
Question:
Corticosteroids, used in the treatment of ulcerative colitis, usually do NOT: increase the rate of infection.
reduce the effectiveness of vaccines.
increase the effectiveness of antibiotics. Correct
increase the risk of developing osteoporosis.
Explanation:
Corticosteroids usually do NOT increase the effectiveness of antibiotics; they reduce their effectiveness. Because they suppress the immune system, they increase the rate of infection, reduce the effectiveness of vaccines and increase the risk of osteoporosis and fractures due to loss of calcium with corticosteroids.
Question:
The plasma elimination half-life of esomeprazole (Nexium) is: 1-1.5 hours. Correct
2-3 hours.
3.5-5 hours.
6-8 hours.
Explanation:
The plasma elimination half-life of esomeprazole (Nexium) is approximately 1 to 1.5 hours. Less than 1% of the parent drug is excreted in the urine. Approximately 80% of an oral dose of esomeprazole is excreted as inactive metabolites in the urine, and the remainder is found as inactive metabolites in the feces.
Question:
Proton pump inhibitors (PPIs), such as pantoprazole (Protonix), block gastrointestinal acid secretion by:
converting cations to anions and pumping from parietal cell to the secretory canaliculus.
prohibiting the pumping of hydrogen ions into the parietal cell. inhibiting the hydrogen-potassium ATPase transport enzyme. Correct inhibiting the sodium-potassium ATPase transport enzyme.
Explanation:
The recognition that H-K-ATPase was the final step of acid secretion culminated in the development of a class of drugs, the proton pump inhibitors (PPIs), which are targeted at inhibiting this enzyme. They are most effective when the parietal cell is stimulated to secrete acid postprandially, a relationship that has important clinical implications for timing of administration. Because the amount of H-K-ATPase present in the parietal cell is greatest after a prolonged fast, PPIs should be administered before the first meal of the day.
Question:
A 7-10 day regimen of ciprofloxacin (Cipro) plus metronidazole (Flagyl) is indicated for the outpatient treatment of:
bacterial vaginosis.
uncomplicated diverticulitis. Correct
Clostridium difficile. gastroenteritis.
Explanation:
A 7-10 day course of oral ciprofloxacin (Cipro) plus metronidazole (Flagyl) is appropriate for the outpatient management of uncomplicated diverticulitis. This regimen provides adequate coverage of common gastrointestinal flora of gram-negative rods and anaerobes.
Question:
Ranitidine (Zantac), a histamine receptor antagonist, is contraindicated in: children.
pancreatitis.
phenylketonuria (PKU). Correct
Zollinger-Ellison disease.
Explanation:
Some H2-blockers contain aspartame. Aspartame is converted to phenylalanine and must be used with caution in patients with PKU. The Pepcid AC brand of famotidine chewable tablets contains 1.4 mg of phenylalanine per 10-mg dose. The Pepcid RPD brand of famotidine oral dispersible tablets contains 1.05 mg of phenylalanine per 20- mg dose. The Zantac brand of ranitidine EFFERdose tablets contains 2.81 mg of phenylalanine per 25-mg dose and 16.84 mg of phenylalanine per 150-mg dose.
Question:
A patient who has been taking a proton pump inhibitor for the last 6 months reports persistent diarrhea for the past 3 weeks. The nurse practitioner should consider:
colitis. gastroparesis.
bacterial gastroenteritis. Clostridium difficile. Correct
Explanation:
The US Food and Drug Administration (FDA) has issued a safety alert encouraging providers to consider a diagnosis of Clostridium difficile-associated disease in PPI users
with persistent diarrhea. Given the potential risk of Clostridium difficile infection, the FDA has also recommended that providers prescribe the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.
Question:
Histamine receptor antagonists (H2RA), such as famotidine (Pepcid), inhibit acid secretions by:
blocking the parietal cells (acid-producers) from responding to histamine. Correct
blocking transport of histamine across the ATPase Pump.
antagonizing the release of histamine from the enterochromaffin-like cells (ECL cells).
antagonizing hydrogen ions from responding to histamine.
Explanation:
H2 blockers inhibit the parietal cells in the stomach lining from responding to histamine. This reduces the amount of acid produced by the stomach. H2RA blockers include: famotidine (Pepcid); ranitidine (Zantac), and nizatidine (Axid).
Question:
The length of treatment for oral metoclopramide should NOT exceed: 4 weeks.
8 weeks.
10 weeks.
12 weeks. Correct Explanation:
Avoid treatment with metoclopramide for longer than 12 weeks in all but rare cases in which therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia. Oral metoclopramide is indicated for adults only.
Question:
A 42-year-old patient is being treated with 40 mg of famotidine (Pepcid) daily for the treatment of duodenal ulcers [Show Less]